BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38476635)

  • 1. Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D.
    Mohan S; Sheehan M; Tebben P; Wermers R
    JCEM Case Rep; 2024 Mar; 2(3):luae022. PubMed ID: 38476635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypervitaminosis D Secondary to a
    Collins L; Boehm E; Luxford C; Clifton-Bligh R; Grill V
    JBMR Plus; 2023 Sep; 7(9):e10788. PubMed ID: 37701149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
    Tebben PJ; Singh RJ; Kumar R
    Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
    Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
    Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect.
    O'Keeffe DT; Tebben PJ; Kumar R; Singh RJ; Wu Y; Wermers RA
    Osteoporos Int; 2016 Oct; 27(10):3121-5. PubMed ID: 27129455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1.
    Arnold N; O'Toole V; Huynh T; Smith HC; Luxford C; Clifton-Bligh R; Eastman CJ
    Endocrinol Diabetes Metab Case Rep; 2019 Nov; 2019():. PubMed ID: 31751313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D.
    Gonciulea AR; Wang Y; Bikle DD; Sellmeyer DE
    Osteoporos Int; 2021 Dec; 32(12):2587-2592. PubMed ID: 34230999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations.
    Carpenter TO
    J Steroid Biochem Mol Biol; 2017 Oct; 173():337-340. PubMed ID: 28093352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal Hypercalcemia Due to Failure of 1,25-Dihydroxyvitamin-D3 Catabolism in a Patient With CYP24A1 Mutations.
    Shah AD; Hsiao EC; O'Donnell B; Salmeen K; Nussbaum R; Krebs M; Baumgartner-Parzer S; Kaufmann M; Jones G; Bikle DD; Wang Y; Mathew AS; Shoback D; Block-Kurbisch I
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2832-6. PubMed ID: 26097993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy.
    Tebben PJ; Milliner DS; Horst RL; Harris PC; Singh RJ; Wu Y; Foreman JW; Chelminski PR; Kumar R
    J Clin Endocrinol Metab; 2012 Mar; 97(3):E423-7. PubMed ID: 22337913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iatrogenic vitamin D toxicity in an infant--a case report and review of literature.
    Ketha H; Wadams H; Lteif A; Singh RJ
    J Steroid Biochem Mol Biol; 2015 Apr; 148():14-8. PubMed ID: 25636720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.
    Figueres ML; Linglart A; Bienaime F; Allain-Launay E; Roussey-Kessler G; Ryckewaert A; Kottler ML; Hourmant M
    Am J Kidney Dis; 2015 Jan; 65(1):122-6. PubMed ID: 25446019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperparathyroidism complicating CYP 24A1 mutations.
    Loyer C; Leroy C; Molin A; Odou MF; Huglo D; Lion G; Ernst O; Hoffmann M; Porchet N; Carnaille B; Pattou F; Kottler ML; Vantyghem MC
    Ann Endocrinol (Paris); 2016 Oct; 77(5):615-619. PubMed ID: 27378451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
    Faiq S; Lavelle K; Hu T; Shoback D; Ku G
    BMC Endocr Disord; 2023 Jun; 23(1):133. PubMed ID: 37328745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.
    Shah R; Licata A; Oyesiku NM; Ioachimescu AG
    Pituitary; 2012 Dec; 15 Suppl 1():S17-22. PubMed ID: 21188640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR.
    Mahajan A; Buse J; Kline G
    Osteoporos Int; 2020 Jan; 31(1):203-207. PubMed ID: 31641801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in the
    Cappellani D; Brancatella A; Kaufmann M; Minucci A; Vignali E; Canale D; De Paolis E; Capoluongo E; Cetani F; Jones G; Marcocci C
    Case Rep Endocrinol; 2019; 2019():4982621. PubMed ID: 31089432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampin monotherapy for children with idiopathic infantile hypercalcemia.
    Lenherr-Taube N; Furman M; Assor E; Thummel K; Levine MA; Sochett E
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106301. PubMed ID: 36990163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercalcemia, nephrolithiasis, and hypervitaminosis D precipitated by supplementation in a susceptible individual.
    Haridas K; Holick MF; Burmeister LA
    Nutrition; 2020 Jun; 74():110754. PubMed ID: 32222584
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.